Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

0 million in the prior year.

Net loss per share applicable to common stockholders during the fourth quarter of 2007 was ($0.19), compared to a net loss per share of ($0.22) in the prior quarter, and a net loss per share of ($0.44) in the comparable quarter of last year. Net loss per share applicable to common stockholders during the full year of 2007 was ($0.96), down from a net loss per share of ($1.38) in the full year of 2006.

"Having received FDA approval for MOXATAG and raising more than $20 million in the first quarter of 2008, we believe we are now in a very favorable position to be considering strategic alternatives for the Company," stated Edward M. Rudnic, Ph.D., president and CEO of MiddleBrook. "We intend to work closely with Morgan Stanley over the coming months to drive the strategic process toward a potential transaction having the greatest benefit for our shareholders."

OPERATIONAL HIGHLIGHTS

Keflex(R) Capsules (Cephalexin, USP) - Commercialization Update

During the fourth quarter, MiddleBrook continued the commercialization of its 750 mg strength Keflex capsules through a targeted and dedicated national contract sales force. Based on prescription data from IMS Health, total prescriptions filled for Keflex 750 mg capsules in the fourth quarter of 2007 were 79,628 prescriptions, compared to third quarter 2007 prescriptions of 83,767.

MiddleBrook is currently marketing Keflex 750 mg capsules through its sales force of approximately 30 contract sales representatives and three MiddleBrook district sales managers.

MOXATAG(TM) (amoxicillin extended-release) Tablets Approval - January 23, 2008

On January 23, 2008, MiddleBrook received U.S. Food and Drug Administration (FDA) approval of the Company's New Drug Application (NDA) for its once-daily amoxicillin PULSYS(R) product, under the trade name, MOXATAG(TM) (amoxicillin extended-release) Tablets. MOXATAG is approved for the treatment of pharyngitis an
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Xencor, Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... appointment of Debra Zack , M.D., Ph.D., ... Lloyd Rowland , senior vice president, chief ... "Debra,s expertise in biologics clinical development and medical ...
(Date:9/2/2014)... Winston-Salem, NC and Rocky Mount, NC (PRWEB) September 02, ... (PMG) announced today the establishment of its 11th clinical ... 1, PMG Research has assumed ownership and operation of ... in Rocky Mount, NC, further expanding PMG’s presence in ... to an additional 130,000 patients. For the patients in ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue: India Solid Waste Management Vehicles ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... governing bodies responsible for complete handling and regulation ... average, around 135,000 MT solid waste is generated ...
(Date:8/31/2014)... Available spectra is similar for all L-series products ... a wide range of plants. The spectra is ... and pending wide spectrum technology. The single chip ... in contrast to growth spectra made from monochromatic ... large variety of differently sized and shaped growing ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:9/1/2014)... decisions of the Nomenclature Section of the XVIII International ... 2011. This meeting is held every six years and ... rules for naming algae, fungi and plants get together ... the organisms they study. This is the primary product ... algae, fungi, and plants, which was published in 2012. ...
(Date:8/31/2014)... fast and accurate tool to diagnose tuberculosis in ... developed test (TAM-TB assay) is the first reliable ... The test features excellent specificity, a similar sensitivity ... a blood test. The promising findings are a ... children, particularly in tuberculosis-endemic regions. , The study ...
(Date:8/31/2014)... of the greatest challenges in modern medicine is developing ... with minimal toxicity and side-effects to the patient. Such ... the drug molecule. Ideally, the drug should have a ... so that it binds it with high specificity. Publishing ... a synthetic amino acid that can impact the 3D ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2New tuberculosis blood test in children is reliable and highly specific 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... WORCESTER, Mass. Orthopedic surgeons are often hamstrung ... bone injuries resulting from trauma, aging or cancer. Conventional ... or brittle ceramics, and cannot readily conform to the ... in addition, they often require metallic fixation devices that ...
... Swiss needle cast epidemic in Douglas-fir forests of the coastal ... over at least the past 100 years, and is probably ... and a warmer climate, new research concludes. Scientists in ... found that this disease, which is affecting hundreds of thousands ...
... the University of Alabama at Birmingham (UAB) have been ... Scholarship and Excellence in Education Foundation. Atbin Doroodchi, ... Biology and Mathematics. He has a 3.95 grade-point average ... Honors Program. Doroodchi is an undergraduate researcher in the ...
Cached Biology News:Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers 2Forest epidemic is unprecedented phenomenon, still getting worse 2Forest epidemic is unprecedented phenomenon, still getting worse 3Forest epidemic is unprecedented phenomenon, still getting worse 43 UAB students awarded prestigious Goldwater scholarships 2
... Clone/PAD: ZMD.358. Immunogen: Synthetic ... region of human mouse and ... with human and mouse LRP5 ... (positive controls: mouse LRP5-pSEC-tag-transfected 293T ...
MarrowMAX Bone Marrow Medium...
... recognizes murine IRF7 protein, and ... related IRF proteins. Reactivity of ... protein was confirmed by western ... cells transfected with IRF7. Reactivity ...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
Biology Products: